‘Excellent’ survival with HCT despite early treatment failure in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL) patients who experience early treatment failure, an analysis of a large transplant registry suggests. Five-year survival rates exceeded 70% for patients who received autologous or matched sibling donor (MSD) transplants, according to... [Read Article]
Print Friendly, PDF & Email

Chemo-free combo provides potential first-line option for FL

Print Friendly, PDF & Email


Attendee at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma (FL). According to investigators, the multicenter, international phase 3 RELEVANCE trial is the first... [Read Article]
Print Friendly, PDF & Email

Polatuzumab plus BR improves efficacy in DLBCL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to randomized phase 2 study results. By contrast, there were no such improvements in... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email

FDA issues CRL for proposed biosimilar rituximab

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed biosimilar rituximab. Sandoz submitted the biologics licensing application for the product, known as GP2013, in September 2017. The company was seeking approval for GP2013 to treat follicular... [Read Article]
Print Friendly, PDF & Email

Inhibitor outperforms rivals in leukemia, lymphoma

Print Friendly, PDF & Email


Researchers in the lab
Photo by Rhoda Baer
Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain hematologic malignancies. In one study, CG’806 proved more potent than comparator drugs in primary samples of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). In another study,... [Read Article]
Print Friendly, PDF & Email

Tazemetostat exhibits antitumor activity in phase 1 trial

Print Friendly, PDF & Email


Micrograph showing DLBCL
The EZH2 inhibitor tazemetostat demonstrated a “favorable safety profile and antitumor activity” in a phase 1 study, according to researchers. The drug produced responses in 8 of 21 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), including 3 complete responses (CRs). The maximum tolerated dose of tazemetostat was not reached, and there were... [Read Article]
Print Friendly, PDF & Email

Duvelisib NDA granted priority review

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for duvelisib, a dual PI3K delta/gamma inhibitor. With this NDA, Verastem, Inc., is seeking full approval of duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval... [Read Article]
Print Friendly, PDF & Email